Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HBV inhibitor
1793065-08-3 (R-isomer) 2093044-32-5 (S-isomer) 1092970-12-1 (racemic) 1646361-04-7 (mesylate) -
IMPDH inhibitor
Merimepodib is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities. -
HBV inhibitor
BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. -
HBV inhibitor
Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. -
HBV Inhibitor
Bersacapavir is an HBV capsid assembly modulator that targets hepatitis B virus (HBV) replication. It exhibits a dual mechanism of action by forming complete genome-free empty capsids and inhibiting the de novo synthesis of covalently closed circular DNA (cccDNA). This compound is valuable for research applications focusing on HBV infection and the development of antiviral therapies. -
HBV RNase H Inhibitor
β-Thujaplicinol is a potent inhibitor of hepatitis B virus (HBV) ribonuclease H, showing inhibitory effects on HBV genotypes D and H with IC50 values of 5.9 and 2.3 μM, respectively. Its primary mechanism involves disrupting the enzymatic activity of HBV RNase H, making it a valuable tool for researching HBV replication and pathogenesis. This compound is suitable for studies focused on antiviral development and the therapeutic targeting of HBV. -
HBV inhibitor
ALG-000184 is an orally bioavailable inhibitor targeting hepatitis B virus (HBV). It functions as a prodrug to ALG-001075 and effectively reduces HBV DNA production in liver cells. This compound is intended for research applications in chronic hepatitis B studies, facilitating investigations into therapeutic strategies against HBV infection.
-
HBV Replication Inhibitor
AT-130 is a phenylpropenamide derivative that serves as a potent non-nucleoside inhibitor of hepatitis B virus (HBV) replication. It effectively inhibits viral DNA synthesis, exhibiting an EC50 of 0.13 μM against both wild-type and mutant strains of HBV. AT-130 demonstrates significant anti-HBV activity in hepatoma cell lines, making it a valuable tool for research focused on HBV infection and treatment strategies. -
HBV Inhibitor
HBV-IN-4 is a phthalazinone derivative that functions as a potent inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. This compound effectively induces the formation of genome-free capsids, demonstrating substantial anti-HBV activity. Its applications include research into therapeutic strategies for hepatitis B virus infections. -
HBV Inhibitor
Alisol F 24-acetate is a triterpenoid compound that targets Hepatitis B Virus (HBV) by inhibiting the secretion of HBV surface antigens HBsAg and HBeAg, with respective IC50 values of 7.7 µM and 5.1 µM. This compound also exhibits proapoptotic activity, making it a valuable agent for cancer research applications. Its role in regulating viral antigen secretion positions it as a potential therapeutic candidate in HBV-related studies. -
HBV Inhibitor
HBV-IN-23 is a potent inhibitor of Hepatitis B virus (HBV) DNA replication with an IC50 of 0.58 μM. This compound effectively inhibits HBV replication across both sensitive and resistant strains. Additionally, HBV-IN-23 demonstrates anti-hepatocellular carcinoma activity by inducing apoptosis in HepG2 cells, making it a valuable tool for research into HBV and related hepatic conditions. -
HBV Inhibitor
HBV-IN-48 is a potent inhibitor of Hepatitis B Virus (HBV) with demonstrated antiviral activity. It effectively reduces viral replication in HepDE19 cells, achieving an EC50 value of 0.005 μM. Additionally, HBV-IN-48 has shown the ability to lower serum HBV DNA levels in mouse models, making it a valuable tool for studying HBV infections and potential therapeutic interventions. -
HBV DNA Synthesis Inhibitor
LB80317 is an active metabolite of LB80380 that functions as a potent inhibitor of HBV DNA synthesis, exhibiting an EC50 of 0.5 μM. This compound demonstrates antiviral activity, making it a promising candidate for the treatment of chronic hepatitis B. Its ability to inhibit viral replication supports its potential utility in HBV research and therapeutic applications. -
HBV Inhibitor
HBV-IN-21 is a potent inhibitor of hepatitis B virus (HBV) DNA replication, exhibiting an IC50 of 2.2 µM. This compound demonstrates a strong interaction with the HBV core capsid protein, characterized by a dissociation constant (KD) of 60.0 μM. HBV-IN-21 is suited for research applications focused on antiviral drug development and elucidation of HBV replication mechanisms. -
HBV Inhibitor
HBV-IN-22 is a potent inhibitor of Hepatitis B Virus (HBV) DNA replication, demonstrating IC50 values of 0.71 μM against wild-type strains and 0.84 μM against resistant strains. This compound is valuable for research focused on antiviral drug development and understanding HBV resistance mechanisms, making it a critical tool in the study of Hepatitis B therapeutics. -
HIV/HBV Inhibitor
L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV. -
HBV Inhibitor
HBV-IN-53 is an inhibitor of Hepatitis B virus (HBV) that effectively reduces serum levels of HBV DNA. Its potent antiviral activity makes it a valuable tool for research in HBV therapeutics. Additionally, HBV-IN-53 has been shown to exhibit an additive inhibitory effect when combined with Tenofovir disoproxil fumarate, highlighting its potential for use in combination therapy studies. -
SIRT Inhibitor
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity. -
HBV Inhibitor
Isoscopoletin, also known as 6-Hydroxy-7-methoxycoumarin, primarily inhibits hepatitis B virus (HBV) replication. It demonstrates significant cytotoxic effects against human CCRF-CEM leukaemia cells and their multidrug-resistant subline, with IC50 values of 4.0 μM and 1.6 μM, respectively. Additionally, Isoscopoletin exhibits anti-inflammatory properties by modulating the MAPK/NF-κB/STAT/AKT signaling pathways, making it a valuable compound for research in virology and cancer biology. -
HBV Inhibitor, EBV Inhibitor
FMAU is a nucleoside analog that primarily inhibits the replication of hepatitis B virus (HBV) and Epstein-Barr virus (EBV). Once phosphorylated by human thymidine kinase, FMAU is incorporated into DNA, serving as a valuable marker for cell proliferation. Its research applications extend to studies on herpes simplex virus infection and various cancer types. -
HBV Inhibitor
Adefovir is an adenosine monophosphate analog that targets HBV DNA polymerase, exerting its inhibitory effects through conversion to Adefovir diphosphate within cells. Demonstrating an IC50 of 0.7 μM against Hepatitis B Virus (HBV) in the HepG2.2.15 cell line, Adefovir exhibits strong antiviral properties against HBV and other herpesviruses. It is a valuable reagent for research into antiviral therapies and HBV-related studies. -
HIV/HBV Inhibitor
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate, a phosphorylated metabolite of Emtricitabine. This compound functions as a nucleoside reverse transcriptase inhibitor, effectively targeting both HIV and HBV. Emtricitabine triphosphate tetrasodium salt is utilized in research applications focused on antiviral drug development and the mechanisms of viral replication. -
HBV Inhibitor
Vebicorvir is a first-generation inhibitor targeting the hepatitis B virus (HBV) core protein. It effectively suppresses the formation of covalently closed circular DNA (cccDNA) in various de novo infection models, demonstrating effective inhibition with EC50 values ranging from 1.84 μM to 7.3 μM. This compound is valuable for research applications focused on developing therapeutic strategies against HBV infections. -
HBV Inhibitor
Inarigivir ammonium is a potent HBV inhibitor that functions as a RIG-I (Retinoic acid-inducible gene-I) agonist, stimulating the innate immune response to combat hepatitis B virus infection. This compound has demonstrated effectiveness in significantly reducing liver HBV DNA levels in transgenic mouse models. Due to its mechanism of action, Inarigivir ammonium is positioned as a valuable tool for research in antiviral therapies and the study of hepatitis B virus dynamics. -
HBV Inhibitor
5-O-(E)-p-Coumaroylquinic acid is a quinic acid derivative that serves as a potent inhibitor of hepatitis B virus (HBV). This compound exhibits significant antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its unique structural properties may provide insights into the development of novel antiviral agents targeting viral replication. -
HBV Inhibitor
Schisantherin C is a potent inhibitor of hepatitis B virus (HBV) with demonstrated efficacy in reducing hepatocyte secretions of HBsAg and HBeAg by 59.7% and 34.7%, respectively, at a concentration of 50 μg/mL. This compound holds potential for research applications aimed at understanding HBV pathogenesis and developing effective antiviral therapies. -
HBV Inhibitor
ALG-001075 functions as a capsid assembly modulator (CAM) and serves as an orally active inhibitor of hepatitis B virus (HBV). This compound effectively inhibits HBV DNA production, along with extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. In the AAV-HBV mouse model, ALG-001075 demonstrates significant reductions in circulating HBV DNA. It is valuable for research applications focused on chronic hepatitis B (CHB). -
HBV Inhibitor
SAG-524 is a highly effective small molecule inhibitor targeting hepatitis B virus (HBV) replication. It demonstrates significant antiviral activity, reducing HBV-DNA and HBsAg levels in supernatants of HepG2.2.15 cells, with IC50 values of 0.92 nM and 1.4 nM, respectively. SAG-524 is valuable for research focused on HBV biology and therapeutic development for liver diseases associated with viral infections. -
HBV Capsid Inhibitor
AB-836 is an orally active inhibitor of the hepatitis B virus (HBV) capsid, targeting the HBV core protein to impede viral replication. This compound is valuable for research focused on chronic hepatitis B, offering insights into antiviral strategies and mechanisms of HBV pathogenesis. Researchers can utilize AB-836 to explore its potential therapeutic applications in HBV-related studies. -
HBV Inhibitor
Xalnesiran sodium is a small interfering RNA (siRNA) designed to inhibit hepatitis B virus (HBV) replication. It provides a valuable tool for researching chronic HBV infections and understanding the virus's biology. This compound is particularly relevant in studies aimed at developing therapeutic strategies for managing HBV-related diseases. -
HBV Inhibitor
CCC-0975 is a selective inhibitor of the hepatitis B virus (HBV), demonstrating an EC50 of 10 μM. This compound effectively disrupts the conversion of relaxed circular DNA (rcDNA) to covalently closed circular DNA (cccDNA), leading to a reduction in both cccDNA and its precursor, deproteinized rcDNA (DP-rcDNA), without inducing their degradation within the cell. CCC-0975 is a valuable tool for research focused on chronic hepatitis B and its associated mechanisms. -
Anti-HBV Inhibitor
IR415 is a potent inhibitor of hepatitis B virus (HBV) replication, primarily functioning by blocking the activity of the HBx protein. It exhibits a high affinity for HBx with a dissociation constant (Kd) of 2 nM, effectively disrupting HBV-mediated RNA interference suppression. By reversing the inhibitory effects of HBx on the dicer endoribonuclease, IR415 serves as a valuable reagent for research into antiviral strategies and mechanisms of HBV pathology. -
HBV Inhibitor
Torcitabine, also known as 2'-Deoxy-L-cytidine, is an antiviral compound targeting hepatitis B virus (HBV) replication. It demonstrates significant inhibitory activity against HBV, making it a valuable agent in the research and development of treatments for chronic HBV infections. Its mechanism of action involves incorporation into viral DNA, effectively disrupting viral replication and propagation. -
HBV Inhibitor
CYP1A1 inhibitor 8a is a selective inhibitor of the CYP1A1 enzyme, showing over 10-fold selectivity for its target and greater than 100-fold selectivity against other CYP1 subfamily enzymes. This compound effectively antagonizes benzo[a]pyrene (B[a]P)-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast models and demonstrates protective effects against CYP1A1-mediated B[a]P cytotoxicity in human cells. Due to its significant inhibitory properties, CYP1A1 inhibitor 8a holds promise as a potential agent for cancer chemoprevention. -
HBV Inhibitor
Neochlorogenic acid methyl ester is an HBV inhibitor that functions as a selective inducer of quinone reductase (EC50 = 6.7 μM) while demonstrating potent hydroxyl radical scavenging activity (EC50 = 0.81 μM). This compound plays a critical role in antioxidant defense by donating electrons or hydrogen atoms to neutralize hydroxyl radicals, thereby promoting carcinogen detoxification. Neochlorogenic acid methyl ester is utilized in research investigating antioxidant damage and metabolic detoxification, particularly within the contexts of cancer chemotherapy and diseases related to oxidative stress. This compound is derived from the flower buds of *L. japonica*. -
HBV Inhibitor
Tiviciclovir is a guanosine analog that acts as a selective inhibitor of hepatitis B virus (HBV). Its primary mechanism involves interfering with viral replication, making it a valuable tool in the study of HBV-associated diseases. This compound is primarily utilized in research focused on antiviral therapy and the development of treatments for chronic hepatitis B infections. -
HBV Inhibitor
2'-Deoxy-L-adenosine is a potent inhibitor of hepatitis B virus (HBV) replication, targeting the viral polymerase with high specificity and selectivity. This compound functions as a synthon for modified oligodeoxyribonucleotides, making it a valuable tool for research focused on HBV and related hepatotropic viruses, including woodchuck and duck hepatitis viruses. Its ability to interfere with viral replication positions it as a significant reagent in studies aimed at understanding and developing therapies for HBV infections. -
HBV Inhibitor
Besifovir Dipivoxil maleate is a potent HBV inhibitor acting as an oral proagent of LB80317. It demonstrates significant efficacy in suppressing hepatitis B virus (HBV) DNA in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patient populations. This compound is valuable for research into therapeutic strategies for managing chronic hepatitis B infections. -
HBV Inhibitor
HBV-IN-46 is a potent inhibitor of Hepatitis B virus (HBV) S-antigen, demonstrating an EC50 value of 2.6 nM. This active metabolite is valuable for research related to HBV infection and presents a promising tool in the development of antiviral therapies targeting HBV. Its specificity and efficacy make it a useful reagent for studying viral replication and host-pathogen interactions in HBV-related research. -
HBV Inhibitor
HBV-IN-43 is a potent inhibitor of Hepatitis B Virus (HBV) replication. This compound demonstrates strong antiviral activity by targeting key viral processes, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its efficacy in inhibiting HBV provides insights into the development of antiviral therapies for Hepatitis B infection. -
HBV Inhibitor
HBV-IN-41 is a potent inhibitor of the Hepatitis B Virus (HBV), exhibiting a remarkable EC50 of 0.027 μM. This orally active compound effectively targets viral replication, making it a valuable tool for research into HBV pathogenesis and potential therapeutic interventions. Its efficacy positions it as a significant reagent for studies aimed at developing new antiviral strategies against HBV. -
HBV Inhibitor
Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine with targeted activity against hepatitis B virus (HBV). It functions as an HBV inhibitor, effectively reducing viral replication and promoting antiviral responses. This compound is primarily utilized in research focusing on HBV infection and the development of therapeutic strategies for managing viral hepatitis. -
HBV Inhibitor
AT-61 is a non-nucleoside inhibitor that targets Hepatitis B virus (HBV) replication. It disrupts the formation of the capsid necessary for pre-genomic RNA, leading to the generation of empty capsids. This compound demonstrates efficacy against drug-resistant HBV mutant strains and is suitable for research focused on HBV infection mechanisms and therapeutic strategies. -
HBV Inhibitor
Xalnesiran is a small interfering RNA (siRNA) specifically designed to inhibit hepatitis B virus (HBV) replication. By targeting and degrading HBV RNA, it plays a crucial role in reducing viral load and the associated liver pathology. Xalnesiran is valuable for research applications focused on chronic hepatitis B treatment strategies and the investigation of RNA interference mechanisms in viral infections. -
HBV Inhibitor
Glaziovine is an antiviral compound derived from Hypserpa nitida, specifically targeting hepatitis B virus (HBV). It demonstrates potent inhibitory activity against HBV, effectively suppressing the secretion of hepatitis B virus surface antigen (HBsAg) in Hep G2.2.15 cells, with an IC50 value of 8 nM. This reagent is valuable for research into antiviral therapies and the mechanisms of HBV infection. -
HBV Inhibitor
Oxynitidine is an HBV inhibitor that demonstrates potent activity against Hepatitis B virus DNA replication, with an ID50 of 30.8 µg/mL. This compound serves as a valuable tool for investigating viral infections and can be utilized in the development of therapeutic interventions targeting HBV. -
HBV/HDV Inhibitor
HBV/HDV-IN-3 is a dual inhibitor targeting Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV), demonstrating an effective EC50 of less than 50 nM against HBV. This compound shows significant antiviral activity and is suitable for research applications focused on the development of therapeutics for HBV and HDV infections. Its effectiveness in inhibiting both viruses makes it a valuable tool for exploring antiviral strategies.
